DoseGear research brief
Non-pegylated IGF-1 splice variant produced locally in muscle tissue following mechanical stress. Has a very short half-life compared to PEG-MGF, requiring more frequent administration or localized injection.
Mechano Growth Factor
Mechano Growth Factor | IGF-1 Splice Variant
DoseGear research brief
Non-pegylated IGF-1 splice variant produced locally in muscle tissue following mechanical stress. Has a very short half-life compared to PEG-MGF, requiring more frequent administration or localized injection.
Activates muscle satellite stem cells via receptor binding, stimulating MAPK/ERK signaling. Enhances protein synthesis and promotes muscle fiber repair. The E-peptide domain exhibits distinct activity from mature IGF-1.
Compound background
Study windows describe what researchers measured, not when an individual should expect a result.
Name associated with the IGF-I Ec splice variant and E-domain research.
Muscle-injury and repair signaling; endogenous splice-product findings do not automatically validate synthetic products.
Not reported for a defined administered MGF product.
Reference data
Not personalized dosing instructions
Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.
| Research context | Amount | Frequency | Route |
|---|---|---|---|
| Standard Protocol | 100-300mcg | Daily, post-workout | IM into target muscle |
| Progressive Titration | 100mcg → 300mcg | Daily, increasing weekly | IM bilateral |
| Localized Recovery | 200-300mcg | Immediately post-workout | IM into worked muscle groups |
Reference cycle
8-12 weeks
Reference storage
Refrigerate at 2-8°C; use within 30 days
MGF-E Peptide Human Muscle Cell Study
Mechano-Growth Factor Minireview
This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.